Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01947920 · ClinicalTrials.gov registry record · Phase 1
A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers
A Phase 1 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01947920 is a Phase 1 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 30 participants.
The verdict
NCT01947920, a Phase 1 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability profile of tramadol hydrochloride (HCl) given as oral doses every 6 hours, within the range of dosages supported by currently available toxicology and clinical data (200 mg to 600 mg per day).
Interventions
- DRUG Placebo
- DRUG Tramadol HCl, 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01947920
The ClinicalTrials.gov registry entry for NCT01947920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01947920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01947920 about?
NCT01947920 is a clinical study titled "A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers". The purpose of this study is to determine the safety and tolerability profile of tramadol hydrochloride (HCl) given as oral doses every 6 hours, within the range of dosages supported by currently available toxicology and clinical data (200 mg to 600 mg per day).
What is the current status of trial NCT01947920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01947920?
The interventions under investigation include: Placebo (DRUG), Tramadol HCl, 50 mg (DRUG).
Who is sponsoring clinical trial NCT01947920?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.